

## JOINT IAEA ORPU – RSTU WEBINAR N°11

---

### TIPS AND TRICKS FOR THE PRACTICE OF INTERNAL DOSIMETRY IN OCCUPATIONAL RADIATION PROTECTION

Wednesday, 7 October 2020

# Challenges of the dosimetry of internal exposures

María Antonia López  
EURADOS – European Radiation Dosimetry Group  
CIEMAT (Madrid, Spain)

# OCCUPATIONAL INTERNAL DOSIMETRY

- **Objective:** Assessment of **the Committed Effective Dose E(50) Sv** due to the radionuclides incorporated into the body through inhalation, ingestion, absorption through intact skin or a wound at the workplace
- **Radiation protection frame:** individual monitoring of exposed persons to ionizing radiations. The assessment of **Effective Dose E (Sv)** to confirm compliance with dose limits:

$$E_t = H_p(10) + \sum_j I_{j,ing} e(g)_{j,ing} + \sum_j I_{j,inh} e(g)_{j,inh}$$

H<sub>p</sub>(10) Sv External Exposures -

E(50) Sv Internal Exposures -

- I<sub>ing</sub>: Intake (Bq) by ingestion
- e(g)<sub>ing</sub>: dose coefficient Sv/Bq – ingestion
- I<sub>inh</sub>: Intake (Bq) by inhalation
- e(g)<sub>inh</sub>: dose coefficient Sv/Bq - inhalation



# Occupational Internal Dosimetry: Challenges

- The **doses due to intakes of radionuclides** can not be obtained directly from measurements but must be assessed from:
  - ✓ In-vivo measurements of the **retained activity  $M(\text{Bq})$**  in total body or organs, using whole/partial Body Counters
  - ✓ In-vitro measurements of the **activity concentration in excreta** samples  $M(\text{Bqd}^{-1}, \text{BqL}^{-1})$
  - ✓ **Activity concentration in the air**  $M(\text{Bqm}^{-3})$

Or by a combination of these methods



# Occupational Internal Dosimetry: Challenges

---

- The interpretation of the **monitoring data** for the assessment of the **intake  $I(\text{Bq})$  and Committed Effective Dose  $E(50) (\text{Sv})$** 
  - requires the application of biokinetic and dosimetric models (ICRP)
  - the evaluator needs to know or to make assumptions about:
    - Type of intake (acute, chronic),
    - Pathway of intake (inhalation, ingestion, injection, intact skin, wound )
    - Time of intake (elapsed time from the exposure and the measurement)
    - Physical (e.g. particle size) and chemical properties of internal contaminants

# Occupational Internal Dosimetry: Challenges

## ICRP Reference documents

### Assessment of **Committed Effective Dose E(50) Sv** for workers

- ICRP Publications 78, 68, 119 (based on ICRP 60 recommendations)
- New ICRP OIR (Occupational Intakes of Radionuclides) reports, Parts I-V (based on ICRP 103 recommendations)
  - ✓ OIR Part I - ICRP Publication 130
  - ✓ OIR Part II - ICRP Publication 134
  - ✓ OIR Part III - ICRP Publication 137
  - ✓ OIR Part IV - ICRP Publication 141
  - ✓ OIR Part V - In progress

$$E(50)Sv = \sum_T W_T \left[ \frac{H_T^M(50) + H_T^F(50)}{2} \right]$$

*E(50) is calculated with the use of male and female committed equivalent doses to individual target organs or tissues T, and the integration time following the intake is taken to be 50 years*

# Occupational Internal Dosimetry: Challenges

---

## General Approach:

### A.- Characterization of internal exposure at the workplace

- Information to be provided (e.g. by the Radiation Protection Officer)

### B.- Design of Routine Monitoring Programs

- Selection of the Monitoring Techniques + monitoring period

### C.- Individual Monitoring of workers:

- Direct and Indirect techniques. Monitoring Data  $M(\text{Bq})$ ,  $M(\text{Bqd}^{-1})$ ,  $M(\text{BqL}^{-1})$

### D.- Assessment of intake and committed effective dose $E(50)$

- Interpretation of Monitoring Data
- Step by step procedure: calculation Intake  $I$  (Bq) and dose  $E(50)$  Sv
- Available commercial software: IMBA, AIDE, IDEA-System, Taurus, Cadzor, ...

# Occupational Internal Dosimetry: Challenges


## A.- Characterization of internal exposure at WORKPLACE

- **Radionuclides:** Type of radiation  $\alpha/\beta/\gamma$ , Energy,  $I_e$ ,  $T_{1/2}, \dots$   
biokinetics (metabolic behaviour inside the body)
- **Chemical compound of the radionuclide:** Absorption Type (F, M, S) in case of inhalation, depending on the solubility of inhaled material:
  - Type F (Fast) – Short time of the radionuclides in the lungs
  - Type M (Moderate) – Medium time in lungs
  - Type S (Slow) – Long time in lungs
  - New ICRP/OIR Reports: also F/M and M/S materials (e.g. Uranium ICRP 137)
- **Particle size of the inhaled aerosol:** AMAD, AMATD  
AMAD: Activity Median Aerodynamic Diameter of inhaled aerosol  
Typically, default value: 5  $\mu\text{m}$  (occupational exposures)

# Occupational Internal Dosimetry: Challenges

## B.- Design of Individual monitoring programs:

- ✓ Selection of technique and monitoring period
  - In vivo and in vitro bioassay will allow:
    - ❖ Identification of radionuclides
    - ❖ Quantification in terms of activity M (Bq) or M(Bq.d<sup>-1</sup>, BqL<sup>-1</sup>)



**ISO20553:** The objective of the monitoring of workers exposed to a risk of internal contamination is to guarantee the detection of the Committed Effective Dose of 1 mSv/year due to internal exposures



# Occupational Internal Dosimetry: Challenges

## C.- Individual monitoring of workers

- **Direct techniques using WBC (Whole Body Counters):**

In vivo measurements of x-rays and gamma emitters internally deposited in the body, using  $\gamma$  spectrometry M (Bq)



- **Indirect techniques:**

✓ In vitro measurements of activity concentration of alpha, beta and gamma emitters in excreta samples M ( $\text{Bqd}^{-1}$ ,  $\text{BqL}^{-1}$ )



✓ Air Samplers: Personal (PAS) or Static (SAS) Air Samplers M ( $\text{Bqm}^{-3}$ )

# Direct techniques using WBC (Whole Body Counters)

**In-vivo monitoring – whole/partial body counting**  
NaI(Tl) and HPGe detectors. Gamma Spectrometry

## (1) Shielded room



CIEMAT WBC

## (2) WBC / Mobile Units



# Direct techniques using WBC (Whole Body Counters)

## In-vivo measurements of gamma emitters in total-body:


- Determination of fission and activation products and other radionuclides deposited in total body.
- **Calibration Phantom:** simulator of the human body, filled with a known radioactive source of radionuclides (e.g.  $^{57}\text{Co}$ ,  $^{113}\text{Sn}$ ,  $^{137}\text{Cs}$ ,  $^{60}\text{Co}$ ,  $^{88}\text{Y}$ ,...) covering the range of energy of interest (e.g. 100-3000 keV)



BOMAB Phantom (ANSI 13.35)



Brick Phantom



ICRU  
Report 69

# Direct techniques using Body Counters: Lung Counting

- In vivo measurement of radionuclides with long residence times in the lung (e.g. U oxides, insoluble Pu and  $^{241}\text{Am}$ ).
- Detection of Xray,  $\gamma$  photons ( $E < 200\text{keV}$ )
- HPGe detectors, Phoswich detectors




## Lung Calibration:

- Livermore (LLNL, USA) phantom or JAERI (Japan) Phantom
- Lungs with radioactive sources
- Chest plates: ribs, muscle and fat
- Counting Efficiency mainly depending on Energy and chest wall thickness.



# Thyroid Counting: determination of radioiodine in thyroid

- **$^{131}\text{I}$ :** gamma emitter with a typical photopeak of 364.5 keV  
Calibration Source:  $^{131}\text{I}$  or  $^{133}\text{Ba}$  (mainly same emissions as  $^{131}\text{I}$  )
- **$^{125}\text{I}$ :** analysis of the X-ray typical emissions of 27.1 keV or/and using the low-energy gamma photopeak of 35.5 keV.  
Calibration Source:  $^{125}\text{I}$  or  $^{129}\text{I}$  (mainly same emissions as  $^{125}\text{I}$ )



ANSI Thyroid Phantom,  
Bottle 20 ml with either  $^{131}\text{I}$   
or  $^{125}\text{I}$  (CIEMAT, Spain)



Livermore Thyroid Phantom,  
IRSN (France)





# INDIRECT TECHNIQUES: In vitro Monitoring of Excreta Samples (Urine and faeces)

## Urine samples:

- ✓ Daily urinary excretion is  $1.6 \text{ Ld}^{-1}$  (reference man) and  $1.2 \text{ Ld}^{-1}$  (reference female)
- ✓ Creatinine is excreted at an average rate of  $1.7 \text{ g d}^{-1}$  (men) and  $1.0 \text{ g d}^{-1}$  (women)  
These values may be used for normalization (24h excretion)

**Fecal samples:** Reference faeces weight for male is 150 g and 120 g for female

## Alpha Spectrometry

- ✓  $^{238}\text{Pu}$ ,  $^{239+240}\text{Pu}$ ,  $^{241}\text{Am}$ ,  $^{244}\text{Cm}$ ,  $^{234}\text{U}$ ,  $^{235}\text{U}$ ,  $^{238}\text{U}$ ,  $^{228}\text{Th}$ ,  $^{230}\text{Th}$ ,  $^{232}\text{Th}$ ,...
- ✓ Radiochemical separation is required
- ✓  $T_c = 300000 \text{ s}$
- ✓ Results in 2-3 weeks



## Liquid Scintillation Counting (LSC) - Beta emitters:

- ✓  $^3\text{H}$  (HTO, OBT),
- ✓  $^{14}\text{C}$ ,  $^{35}\text{S}$ ,  $^{32}\text{P}$ ,
- ✓  $^{90}\text{Sr}$  (radiochemical separation)
- ✓  $T_c = 60 - 120 \text{ min}$
- ✓ Results in 1 day ( $^{90}\text{Sr}$  in  $\sim 5$  days)



# INDIRECT TECHNIQUES: In vitro Monitoring of Excreta Samples (Urine And Faeces)

## Mass Spectrometry **ICP-MS** (Inductively Coupled Plasma Mass Spectrometry )

- ✓ Uranium,  $^{232}\text{Th}$ ,  $^{239}\text{Pu}$ ,...
- ✓ Rapid alternative vs. Alpha Spec.
- ✓ Easy sample treatment, diluted Urine samples
- ✓ Results in 1-2 days



## Mass Spectrometry **TIMS** (Thermal Ionisation Mass Spectrometry)

- ✓ uranium and plutonium isotopic measurements

## Kinetic Phosphorescence Analyser (KPA) and Fluorimetry

- ✓ Methods for total uranium in urine.
- ✓ Rapid alternative vs Alfa Spectrometry but higher Detection Limits



## Gamma Spectrometry

- ✓ Gamma emitters. Rapid method. No sample treatment. Results in 1 day
- ✓ HP Ge detectors

## Comparison of methods for individual monitoring of intakes of radionuclides

Methods	Advantages	Limitations
<p><b>In vivo monitoring</b> of radionuclides in an organ or in total body</p>	<p>Rapid measurement of the activity retained and deposited in the body, especially important in case of RN emergencies</p> <p>Rapid intake and dose assessments</p>	<p>Mainly X<sub>ray</sub> + <math>\gamma</math> emitter radionuclides</p> <p>Physical phantoms simulating internal contamination of organs or total body not always available</p> <p>Worse detection limit for actinide and NORM exposures when comparing with in vitro bioassay</p>
<p><b>In vitro radiobioassay</b> of excreta samples</p>	<p>In vitro bioassay is the measurement technique of choice to quantify internal contamination of pure alpha and beta emitters.</p> <p>Alpha Spec. and ICP-MS: excellent detection limits</p>	<p>Alpha spectrometry: long time (~2 weeks) for estimating activity concentration in excreta samples.</p> <p>ICP-MS: better for NatU and Th in urine samples (and for other long lived radionuclides e.g. <sup>239</sup>Pu) but expensive technique</p>
<p><b>Workplace monitoring, Air Sampling</b></p>	<p>PAS and SAS may be useful when available <i>in vivo</i> and <i>invitro</i> techniques only quantify exposures reliably above 6 mSv, e.g. for monitoring actinides</p>	<p>High uncertainties may be associated when calculating intake, then difficult to use for dose assessment</p>



# Interpretation of Monitoring Data for the assessment of Intake I(Bq) and dose E(50)

## D1.- Intake and Dose Assessments from a **single monitoring data**

- Date/Time of Intake  $T_0$  (dd/mm/yyyy)
- Date/Time of Monitoring: t (days) after Intake
- In vivo monitoring data: M(Bq) Activity (from WBC)  
In vitro monitoring data: M(Bqd<sup>-1</sup>) Activity concentration in excreta samples
- **Assessment of Intake I (Bq)** from a single monitoring data M(Bq):

$$I = \frac{M}{m(t)}$$

M(Bq) = monitoring data (WBC or excreta)  
m(t) = fraction of retained/excreted activity when Intake is 1 Bq (provided by ICRP reports)

- **Assessment of the Committed Effective Dose E(50) mSv:**

$$E(50) \text{ mSv} = I(\text{Bq}) * e(50)(\text{mSv/Bq})$$

e(50) mSv/Bq: dose coefficient (provided by ICRP) =  
committed effective dose PER UNIT INTAKE


# m(t): Retention and Excretion Functions (urine and feces)

$$I = \frac{M}{m(t)}$$

**ICRP provides m(t): retention/excretion functions.**

Fraction in the body (direct measurement) or being excreted from the body (indirect measurement) PER UNIT INTAKE

ICRP: m(t) I-131 inhalation, type F, AMAD= 5 μm



m(t) depends on:

- Physical half-life
- Biokinetics of the radionuclide
- Is a function of the time since intake


**AIDE Software**

# New ICRP/OIR reports: $z(t)$ dose coefficient per measurement content

$$z(t) = \frac{e(50)}{m(t)} Sv Bq^{-1}$$

Values of **dose per unit content** functions  $z(t)$  are provided by ICRP in its Occupational Intakes of Radionuclides (OIR) report series

$$E(50) Sv = M(Bq) \times Z(t) Sv Bq^{-1}$$



**Dose per content function  $z(t)$  for  $^{60}\text{Co}$  from ICRP DATA VIEWER**  
Last update: Electronic Annex OIR P4 (ICRP 141) [www.icrp.org](http://www.icrp.org)

## Assessment of Intake and Dose E(50). Uncertainties.

ISO 27048: Dose Assessment for the monitoring of workers for internal radiation exposure

IDEAS Guidelines: General Guidelines for the Estimation of Committed Effective Dose from Incorporation monitoring data



'Measurements are assumed to be lognormally distributed with a given scattering factor (SF)''

$$SF_i = \exp \sqrt{[\ln(SF_A)]^2 + [\ln(SF_B)]^2}$$

## Assessment of Intake and Dose E(50). Uncertainties.

### ISO 27048 (Annex B, Table B.1. )

Sources of Uncertainties – In-vivo SCATTERING FACTOR (Log-normal)

Result of WBC:  $A \pm 2\sigma_A$  Bq

Calculation of  $SF_A$  from  $\sigma_A \rightarrow SF_A = \exp(\sigma_A/A)$

Source of uncertainty (Type)	Log-normal scattering factor $K_{SF}$		
	Low photon energy $E < 20$ keV	Intermediate photon energy $20$ keV $< E < 100$ keV	High photon energy $E > 100$ keV
Counting statistics (A)	1,5	1,3	1,07
Variation of detector positioning (B)	1,2	1,05	< 1,05
Variation of background signal (B)	1,5	1,1	< 1,05
Variation in body dimensions (B)	1,5	1,12	1,07
Variation of overlaying structures (B)	1,3	1,15	1,12
Variation of activity distribution (B)	1,3	1,05	< 1,05
Calibration (B)	1,05	1,05	1,05
Spectrum evaluation <sup>1)</sup> (B)	1,15	1,05	1,03

## Assessment of Intake and Dose E(50). Uncertainties.

### ISO 27048 (Annex B, Table B.2. )

Uncertainties – In-vivo monitoring, different ranges of energy

	Scattering Factor (Log-normal)		
	Low Energy Photons E < 20 keV	Intermediate Energy Photons 20 keV < E < 100 keV	High Energy Photons E > 100 keV
<b>Total Type A</b>	<b>1.5</b>	<b>1.3</b>	<b>1.07</b>
<b>Total Type B</b>	<b>2.06</b>	<b>1.25</b>	<b>1.15</b>
<b>Total</b>	<b>2.3</b>	<b>1.4</b>	<b>1.2</b>

## Assessment of Intake and Dose E(50). Uncertainties.

### ISO 27048 (Annex B, Table B.3.)

Type B Uncertainties – In vitro monitoring – Default values for  $SF_B$

Quantity	Type B Scattering factor $SF_B$
True 24 h urine	1.1
Activity concentration $^3H$ in urine	1.1
Simulated 24 h urine, creatinine or specific gravity normalised	1.7
Spot urine sample	2.0
Faecal 24 h sample	3.0
Faecal 72 h sample	1.9

## Assessment of Intake and Dose E(50). Uncertainties

### D2. Internal Dose Assessments from a set of n monitoring data $M_i, i= 1...n$

- Date/Time of Intake  $T_0$  (dd/mm/yyyy)
- Date/Time of n Monitoring data:  $t_i$  (days) post intake;  $i= 1, \dots, n$
- Result of In-vivo monitoring:  $M_i$  (Bq) Activity (from WBC) or  
In-vitro monitoring:  $M_i$  (Bqd<sup>-1</sup>) Activity concentration in excreta
- Assessment of the Intake  $I$  (Bq) from a set of n monitoring data

### MAXIMUM LIKELIHOOD METHOD

$$\ln(I) = \frac{\sum_{i=1}^n \left( \frac{\ln(I_i)}{(\ln SF_i)^2} \right)}{\sum_{i=1}^n \frac{1}{(\ln SF_i)^2}}$$

✓  $SF_i$  is the scattering factor (uncertainty) associated to monitoring value  $M_i$

✓  $I_i$  (Bq) is the value of intake obtained from  $M_i$  (Bq, Bq/d):

$$I_i = \frac{M_i}{m(t_i)}$$

- Assessment of the Committed Effective Dose E(50) mSv:

$$E(50) \text{ mSv} = I(\text{Bq}) * e(50)(\text{mSv/Bq})$$

ISO 27048  
IDEAS Guidelines



## Reference Documents on Internal Dosimetry

### ➤ ISO Reference documents - ISO TC85/SC2/WG13

- **ISO 20553:** Monitoring of workers exposed to a risk of internal contamination
- **ISO 28218:** Performance Criteria for Radiobioassay
- **ISO 27048:** Dose Assessment for the monitoring of workers for internal radiation exposure




- **ISO 16637:** Monitoring and internal dosimetry for staff exposed to **medical radionuclides** as unsealed sources
- **ISO 16638-1:** Monitoring and internal dosimetry for specific materials — Part 1: **Inhalation of uranium** compounds.
- **ISO 16638-2:** : Monitoring and internal dosimetry for specific materials — Part 2: **Ingestion of uranium** compounds.
- **ISO 20031:** Monitoring and dosimetry for internal exposures due to **wound contamination** with radionuclides

# Reference Documents on Internal Dosimetry

## ➤ IAEA Reference documents

❑ **GSG-7 - IAEA Safety Guide on Occupational Radiation Protection (2018)**



❑ It combines all the relevant safety guides on the protection of workers into a **single comprehensive safety guide, including the existing Safety Guide RS-G-1.2 Assessment of Occupational Exposure due to Intakes of Radionuclides (1999)** which was superseded when GSG-7 was published.



# Reference Documents on Internal Dosimetry

## ➤ EURADOS Reference documents:

- **EC RP 188** - Technical Recommendations for Monitoring Individuals for Occupational Intakes of Radionuclides ([ec.europa.eu/energy/sites/ener/files/rp\\_188.pdf](http://ec.europa.eu/energy/sites/ener/files/rp_188.pdf))  
*European Commission's Radiation Protection Report Series*



- **IDEAS Guidelines:** General Guidelines for the Estimation of Committed Effective Dose from Incorporation monitoring data.  
[Eurados Report 01-2013 \(www.eurados.org\)](http://www.eurados.org).

## EC RP 188 - Technical Recommendations for Monitoring Individuals for Occupational Intakes of Radionuclides

- A. Purpose, Context and Scope, and Implementation by Internal Dosimetry Services (5 recommendations)
- B. General Principles of Monitoring Individuals for Occupational Intakes of Radionuclides
- C. Monitoring Programmes (19 recommendations)
- D. Methods of Individual and Workplace Monitoring (39 recommendations)
- E. Routine and Special Dose Assessment (29 recommendations)
- F. Accuracy Requirements and Uncertainty Analysis (8 recommendations)
- G. Quality Assurance and Criteria for Approval & Accreditation (14 recommendations)
- H. Radon Measurement and Dosimetry for Workers (15 recommendations)

### ANNEXES

- ✓ Reference Biokinetic and Dosimetric Models
- ✓ Examples of Monitoring Programme Design and Internal Dose Assessment
- ✓ Monitoring and Internal Dosimetry for First Responders in a Major Accident
- ✓ Internal Dosimetry for Assessment of Risk to Health
- ✓ Compilation of the Recommendations

# EC RP 188 - Technical Recommendations for Monitoring Individuals for Occupational Intakes of Radionuclides

Each relevant topic: a question, a technical explanation and list of recommendations

- Chapter D, Methods of Individual and Workplace Monitoring:

**Q2:** How should *in vivo* bioassay of the activity of radionuclides retained in the body that emit penetrating radiation be performed?

D02	I	<b>In vivo measurement</b> of radionuclides in the body should be employed <b>for radionuclides emitting penetrating radiation</b> that can be detected outside of the body (mainly high energy X-ray and gamma emitting radionuclides) wherever feasible [ICRU 2003; IAEA 1996]. Methods should satisfy the <b>performance criteria</b> for radiobioassay set by <b>ISO 28218:2010</b> [ISO 2010b].
D03	I	For radionuclides that are X/gamma emitters (>100 keV) and are rapidly absorbed from the respiratory tract into the body (e.g. <sup>137</sup> Cs, <sup>60</sup> Co), <b>whole body monitoring</b> using <b>NaI(Tl)</b> scintillation detectors and/or <b>HPGe</b> semiconductor detectors should be performed [ICRU 2003; IAEA 1996]
D04	I	<b>Monitoring of specific organs</b> using NaI(Tl) scintillation detectors and/or HPGe semiconductor detectors should be performed for X/gamma emitting radionuclides that concentrate in particular organs or tissues (e.g. <sup>131</sup> I in the thyroid) [ICRU 2003; IAEA 1996]

## Types of Recommendations



- M –Mandatory (e.g. EURATOM Directive)
- I – International (e.g. ICRP, ISO)
- A –Advisory (e.g. TECHREC team)



**EC RP 188**

**ROUTINE MONITORING**

**SPECIAL MONITORING**



# EURADOS e. V. a sustainable network ([www.eurados.org](http://www.eurados.org))

## European Radiation Dosimetry Group



EURADOS was founded in 1981 by scientists involved in contracts with the European Commission.

Main EURADOS bodies:

- ✓ The General Assembly , composed by **80 Voting Members** (Feb 2020)
- ✓ The Executive Board
- ✓ The Council
- ✓ The Working Groups, with the involvement of **> 500 scientists** in different fields of the dosimetry of ionizing radiations
- ✓ **40 Sponsor institutions**



Home | Subscribe to our newsletter | Contact | Sitemap | Members login

EURADOS European Radiation Dosimetry Group

About us Working Groups Documents & Publications EURADOS Actions News Sponsors Links

Dosimetry in medical applications

**Latest News**

- > 2020-10-01 EURADOS newsletter
- > 2020-09-21 EURADOS newsletter
- > 2020-09-09 EURADOS newsletter
- > [More News...](#)

**The European Radiation Dosimetry Group**

We are a network of more than 79 European institutions (Voting Members) and 627 scientists (Associate Members). (Status 01.02.2020)

**Our activities encompass:**

- > Coordination of working groups
  - > which promote technical development and its implementation in routine work
  - > which contribute to compatibility within Europe and conformance with international practices
- > Organization of scientific meetings and training activities
- > Organization of intercomparisons and benchmark studies

**Our areas of activity:**

- > Individual monitoring for external and internal exposure
- > Retrospective dosimetry
- > Environmental radiation monitoring
- > Diagnostic and interventional radiology
- > Nuclear medicine
- > Radiation therapy
- > Computational dosimetry

**Announcements**

- > [EURADOS Report 2020-04: "Visions for Radiation Dosimetry over the Next Two Decades - Strategic Research Agenda of the European Radiation Dosimetry Group: Version 2020" was published](#)
- > [Announcement of the EURADOS Intercomparison 2020 for whole body dosimeters \(IC2020wb\)](#)
- > [EURADOS Report 2020-03: "EURADOS Intercomparison 2016 for Whole Body Dosimeters in Photon and Mixed Radiation Fields" was published.](#)
- > [EURADOS YOUNG SCIENTIST AWARD AND GRANT 2020 is launched. The application deadline is 9 October 2020.](#)
- > [EURADOS Report 2020-02 "ISO/IEC 17025: Guidance for IMS: Suggestions on How to Interpret and Implement the Requirements Including Examples from Accredited](#)

## EURADOS e. V. a sustainable network

([www.eurados.org](http://www.eurados.org))

EURADOS Working Groups
WG2 Harmonisation of individual monitoring
WG3 Environmental dosimetry
WG6 Computational dosimetry
<b>WG7 Internal dosimetry</b> →
WG9 Radiation dosimetry in radiotherapy
WG10 Retrospective dosimetry
WG11 High energy radiation fields
WG12 Dosimetry in medical imaging

### EURADOS actions

- Annual Meetings
- Winter Schools
- Workshops
- **Intercomparisons: EIVIC (WBC)**  
**ICIDOSE (E(50))**
- Training Courses
- Young scientist support
- Newsletter
- EURADOS Reports & publications

- Recent **EC Projects**: EIVIC, EJP CONCERT, CONFIDENCE, Cathymara, Shamiseng, TECHREC,...
- Member of MEENA Network – Joint research for radiological protection in Europe

 EURADOS  
European Radiation Dosimetry Group e. V.

EURADOS Report 2013-01  
Braunschweig, March 2013

**IDEAS Guidelines (Version 2)**  
for the Estimation of Committed Doses  
from Incorporation Monitoring Data

C.M. Castellani, J.W. Marsh, C. Hurtgen,  
E. Blanchardon, P. Berard, A. Giussani,  
M.A. Lopez



Thanks for your  
attention